Comparative efficacy of blood cell immunocamouflage by membrane grafting of methoxypoly(ethylene glycol) and polyethyloxazoline

Biomaterials

Volumn 35, Issue 1, 2014, Pages 412-422

  Kyluik Price, Dana L ^a,b   Li, Li ^a   Scott, Mark D ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Immunocamouflage; Leukocyte; Methoxypoly(ethylene glycol); Polyethyloxazoline; Polymer; Red blood cell

Indexed keywords

IMMUNOCAMOUFLAGE; LEUKOCYTE; METHOXYPOLY(ETHYLENE GLYCOL); POLYETHYLOXAZOLINE; RED BLOOD CELL;

ANTIGEN-ANTIBODY REACTIONS; ANTIGENS; BIOLOGICAL MEMBRANES; BLOOD; CELLS; CYTOLOGY; ETHYLENE GLYCOL; GRAFTING (CHEMICAL); MORPHOLOGY; POLYMERS; POLYOLS;

MOTION PICTURE EXPERTS GROUP STANDARDS;

HLA ANTIGEN; MACROGOL DERIVATIVE; MEMBRANE ANTIGEN; METHOXYPOLY(ETHYLENE GLYCOL); OXAZOLINE DERIVATIVE; POLYETHYLOXAZOLINE; RHESUS D ANTIBODY; UNCLASSIFIED DRUG;

ANTIGEN BINDING; ANTIGEN RECOGNITION; ARTICLE; CELL STRUCTURE; CELL VIABILITY; CLINICAL EFFECTIVENESS; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; ENGRAFTMENT; ERYTHROCYTE; HUMAN; HUMAN CELL; IMMUNOCAMOUFLAGE; IMMUNOREGULATION; IN VITRO STUDY; LEUKOCYTE; PHAGOCYTOSIS; PRIORITY JOURNAL;

IMMUNOCAMOUFLAGE; LEUKOCYTE; METHOXYPOLY(ETHYLENE GLYCOL); POLYETHYLOXAZOLINE; POLYMER; RED BLOOD CELL;

ERYTHROCYTE MEMBRANE; HUMANS; LYMPHOCYTE CULTURE TEST, MIXED; OXAZOLES; POLYETHYLENE GLYCOLS; POLYMERS;

EID: 84887020966     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2013.09.016     Document Type: Article

References (51)

1. Abuchowski A., McCoy J.R., Palczuk N.C., van Es T., Davis F.F. Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase. JBiol Chem 1977, 252:3582-3586.
2. Abuchowski A., van Es T., Palczuk N.C., Davis F.F. Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol. JBiol Chem 1977, 252:3578-3581.
3. Abuchowski A., Kazo G.M., Verhoest C.R.J., Van Es T., Kafkewitz D., Nucci M.L., et al. Cancer therapy with chemically modified enzymes. I. Antitumor properties of polyethylene glycol-asparaginase conjugates. Cancer Biochem Biophys 1984, 7:175-186.
4. Greenwald R.B., Choe Y.H., McGuire J., Conover C.D. Effective drug delivery by PEGylated drug conjugates. Adv Drug Deliv Rev 2003, 55:217-250.
5. Haag R., Kratz F. Polymer therapeutics: concepts and applications. Angew Chem Int Ed Engl 2006, 45:1198-1215.
6. Kang J.S., Deluca P.P., Lee K.C. Emerging PEGylated drugs. Expert Opin Emerg Drugs 2009, 14:363-380.
7. Mehvar R. Modulation of the pharmacokinetics and pharmacodynamics of proteins by polyethylene glycol conjugation. JPharm Pharm Sci 2000, 3:125-136.
8. Pasut G., Sergi M., Veronese F.M. Anti-cancer PEG-enzymes: 30 years old, but still a current approach. Adv Drug Deliv Rev 2008, 60:69-78.
9. Webster R., Didier E., Harris P., Siegel N., Stadler J., Tilbury L., et al. PEGylated proteins: evaluation of their safety in the absence of definitive metabolism studies. Drug Metab Dispos 2007, 35:9-16.
10. Scott M.D., Murad K.L., Koumpouras F., Talbot M., Eaton J.W. Chemical camouflage of antigenic determinants: stealth erythrocytes. Proc Natl Acad Sci U S A 1997, 94:7566-7571.
11. Murad K.L., Gosselin E.J., Eaton J.W., Scott M.D. Stealth cells: prevention of major histocompatibility complex class II-mediated T-cell activation by cell surface modification. Blood 1999, 94:2135-2141.
12. Murad K.L., Mahany K.L., Brugnara C., Kuypers F.A., Eaton J.W., Scott M.D. Structural and functional consequences of antigenic modulation of red blood cells with methoxypoly(ethylene glycol). Blood 1999, 93:2121-2127.
13. Scott M.D., Bradley A.J., Murad K.L. Camouflaged blood cells: low-technology bioengineering for transfusion medicine?. Transfus Med Rev 2000, 14:53-63.
14. Bradley A.J., Murad K.L., Regan K.L., Scott M.D. Biophysical consequences of linker chemistry and polymer size on stealth erythrocytes: size does matter. Biochim Biophys Acta 2002, 1561:147-158.
15. Chen A.M., Scott M.D. Comparative analysis of polymer and linker chemistries on the efficacy of immunocamouflage of murine leukocytes. Artif Cells Blood Substit Immobil Biotechnol 2006, 34:305-322.
16. Le Y., Scott M.D. Immunocamouflage: the biophysical basis of immunoprotection by grafted methoxypoly(ethylene glycol) [mpeg]. Acta Biomater 2010, 6:2631-2641.
17. Wang D., Toyofuku W.M., Chen A.M., Scott M.D. Induction of immunotolerance via mPEG grafting to allogeneic leukocytes. Biomaterials 2011, 32:9494-9503.
18. Wang D., Toyofuku W.M., Scott M.D. The potential utility of methoxypoly(ethylene Glycol)-mediated prevention of rhesus blood group antigen RhD recognition in transfusion medicine. Biomaterials 2012, 33:3002-3012.
19. Wang D., Kyluik D.L., Murad K.L., Toyofuku W.M., Scott M.D. Polymer-mediated immunocamouflage of red blood cells: effects of polymer size on antigenic and immunogenic recognition of allogeneic donor blood cells. Sci China Life Sci 2011, 54:589-598.
20. Chen A.M., Scott M.D. Immunocamouflage: prevention of transfusion-induced graft-versus-host disease via polymer grafting of donor cells. JBiomed Mater Res A 2003, 67:626-636.
21. McCoy L.L., Scott M.D. Broad spectrum antiviral prophylaxis: Inhibition of viral infection by polymer grafting with methoxypoly(ethylene glycol). Antiviral drug discovery for emerging diseases and bioterrorism threats 2005, 379-395. Wiley & Sons, Hoboken, NJ. T. PF (Ed.).
22. Sutton T.C., Scott M.D. The effect of grafted methoxypoly(ethylene glycol) chain length on the inhibition of respiratory syncytial virus (RSV) infection and proliferation. Biomaterials 2010, 31:4223-4230.
23. Kyluik D.L., Sutton T.C., Le Y., Scott M.D. Chapter 7: polymer-mediated broad spectrum antiviral prophylaxis: utility in high risk environments. Progress in molecular and environmental bioengineering- from analysis and modeling to technology applications 2011, 167-190. Intech, Rijeka. A. Carpi (Ed.).
24. Moghimi S.M., Hamad I., Andresen T.L., Jorgensen K., Szebeni J. Methylation of the phosphate oxygen moiety of phospholipid-methoxy(polyethylene glycol) conjugate prevents PEGylated liposome-mediated complement activation and anaphylatoxin production. FASEB J 2006, 20:2591-2593.
25. Armstrong J.K., Leger R.M., Wenby R.B., Meiselman H.J., Garratty G., Fisher T.C. Occurrence of an antibody to poly(ethylene glycol) in normal donors. Blood 2003, 102:556a.
26. Sroda K., Rydlewski J., Langner M., Kozubek A., Grzybek M., Sikorski A.F. Repeated injections of PEG-PE liposomes generate anti-PEG antibodies. Cell Mol Biol Lett 2005, 10:37-47.
27. Armstrong J.K., Hempel G., Koling S., Chan L.S., Fisher T., Meiselman H.J., et al. Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients. Cancer 2007, 110:103-111.
28. Garay R.P., El-Gewely R., Armstrong J.K., Garratty G., Richette P. Antibodies against polyethylene glycol in healthy subjects and in patients treated with PEG-conjugated agents. Expert Opin Drug Deliv 2012, 9:1319-1323.
29. Ganson N.J., Kelly S.J., Scarlett E., Sundy J.S., Hershfield M.S. Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase. Arthritis Res Ther 2006, 8:R12.
30. Ishida T., Kiwada H. Accelerated blood clearance (ABC) phenomenon upon repeated injection of PEGylated liposomes. Int J Pharm 2008, 354:56-62.
31. Ishida T., Kiwada H. Anti-polyethyleneglycol antibody response to PEGylated substances. Biol Pharm Bull 2013, 36:889-891.
32. Chapanian R., Constantinescu I., Brooks D.E., Scott M.D., Kizhakkedathu J.N. Invivo circulation, clearance, and biodistribution of polyglycerol grafted functional red blood cells. Biomaterials 2012, 33:3047-3057.
33. Chapanian R., Constantinescu I., Rossi N.A., Medvedev N., Brooks D.E., Scott M.D., et al. Influence of polymer architecture on antigens camouflage, CD47 protection and complement mediated lysis of surface grafted red blood cells. Biomaterials 2012, 33:7871-7883.
34. Kainthan R.K., Brooks D.E. Invivo biological evaluation of high molecular weight hyperbranched polyglycerols. Biomaterials 2007, 28:4779-4787.
35. Rossi N.A., Constantinescu I., Kainthan R.K., Brooks D.E., Scott M.D., Kizhakkedathu J.N. Red blood cell membrane grafting of multi-functional hyperbranched polyglycerols. Biomaterials 2010, 31:4167-4178.
36. Viegas T.X., Bentley M.D., Harris J.M., Fang Z., Yoon K., Dizman B., et al. Polyoxazoline: chemistry, properties, and applications in drug delivery. Bioconjug Chem 2011, 22:976-986.
37. Mero A., Fang Z., Pasut G., Veronese F.M., Viegas T.X. Selective conjugation of poly(2-ethyl 2-oxazoline) to granulocyte colony stimulating factor. JControl Release 2012, 159:353-361.
38. Bradley A.J., Scott M.D. Separation and purification of methoxypoly(ethylene glycol) grafted red blood cells via two-phase partitioning. JChromatogr B Analyt Technol Biomed Life Sci 2004, 807:163-168.
39. van Kampen E.J., Zijlstra W.G. Standardization of hemoglobinometry. Clin Chim Acta 1961, 6:538-544.
40. Branch D.R., Gallagher M.T., Mison A.P., Sy Siok Hian A.L., Petz L.D. Invitro determination of red cell alloantibody significance using an assay of monocyte-macrophage interaction with sensitized erythrocytes. Br J Haematol 1984, 56:19-29.
41. Rampersad G.C., Suck G., Sakac D., Fahim S., Foo A., Denomme G.A., et al. Chemical compounds that target thiol-disulfide groups on mononuclear phagocytes inhibit immune mediated phagocytosis of red blood cells. Transfusion 2005, 45:384-393.
42. Gallagher M.T., Branch D.R., Mison A., Petz L.D. Evaluation of reticuloendothelial function in autoimmune hemolytic anemia using an invitro assay of monocyte-macrophage interaction with erythrocytes. Exp Hematol 1983, 11:82-89.
43. Karamatic Crew V., Poole J., Long S., Warke N., Colavecchia C., Burton N., et al. Two MER2-negative individuals with the same novel CD151 mutation and evidence for clinical significance of anti-MER2. Transfusion 2008, 48:1912-1916.
44. Arndt P.A., Garratty G. Aretrospective analysis of the value of monocyte monolayer assay results for predicting the clinical significance of blood group alloantibodies. Transfusion 2004, 44:1273-1281.
45. Nance S.J., Arndt P., Garratty G. Predicting the clinical significance of red cell alloantibodies using a monocyte monolayer assay. Transfusion 1987, 27:449-452.
46. Bradley A.J., Scott M.D. Immune complex binding by immunocamouflaged [poly(ethylene glycol)-grafted] erythrocytes. Am J Hematol 2007, 82:970-975.
47. Le Y., Li L., Wang D., Scott M.D. Immunocamouflage of latex surfaces by grafted methoxypoly(ethylene glycol) (mPEG): proteomic analysis of plasma protein adsorption. Sci China Life Sci 2012, 55:191-201.
48. Damodaran V.B., Fee C.J., Ruckh T., Popat K.C. Conformational studies of covalently grafted poly(ethylene glycol) on modified solid matrices using X-ray photoelectron spectroscopy. Langmuir 2010, 26:7299-7306.
49. Heuberger M., Drobek T., Spencer N.D. Interaction forces and morphology of a protein-resistant poly(ethylene glycol) layer. Biophys J 2005, 88:495-504.
50. Rex S., Zuckermann M.J., Lafleur M., Silvius J.R. Experimental and Monte Carlo simulation studies of the thermodynamics of polyethyleneglycol chains grafted to lipid bilayers. Biophys J 1998, 75:2900-2914.
51. Mankelow T.J., Satchwell T.J., Burton N.M. Refined views of multi-protein complexes in the erythrocyte membrane. Blood Cells Mol Dis 2012, 49:1-10.